deSolms S Jane, Ciccarone Terrence M, MacTough Suzanne C, Shaw Anthony W, Buser Carolyn A, Ellis-Hutchings Michelle, Fernandes Christine, Hamilton Kelly A, Huber Hans E, Kohl Nancy E, Lobell Robert B, Robinson Ronald G, Tsou Nancy N, Walsh Eileen S, Graham Samuel L, Beese Lorena S, Taylor Jeffrey S
Departments of Medicinal Chemistry and Cancer Research, Merck Research Laboratories, West Point, Pennsylvania 19486, USA.
J Med Chem. 2003 Jul 3;46(14):2973-84. doi: 10.1021/jm020587n.
A series of novel diaryl ether lactams have been identified as very potent dual inhibitors of protein farnesyltransferase (FTase) and protein geranylgeranyltransferase I (GGTase-I), enzymes involved in the prenylation of Ras. The structure of the complex formed between one of these compounds and FTase has been determined by X-ray crystallography. These compounds are the first reported to inhibit the prenylation of the important oncogene Ki-Ras4B in vivo. Unfortunately, doses sufficient to achieve this endpoint were rapidly lethal.
一系列新型二芳基醚内酰胺已被鉴定为蛋白质法尼基转移酶(FTase)和蛋白质香叶基香叶基转移酶I(GGTase-I)的强效双重抑制剂,这两种酶参与Ras的异戊二烯化。其中一种化合物与FTase形成的复合物结构已通过X射线晶体学确定。这些化合物是首次报道在体内抑制重要癌基因Ki-Ras4B的异戊二烯化。不幸的是,足以达到这一终点的剂量会迅速致死。